A double-blind, placebo-controlled, dose-escalation, phase 1 study was performed in 60 healthy subjects between 18 and 49 years of age. The two-dose regimen induced the development of neutralizing antibodies in high percentages of the subjects (from 88% to 100% of subjects depending on antigen content)”.
The authors analyzed data on 444 imported cases of methicillin-resistant Staphylococcus aureus (MRSA) in Sweden during the period 2000-2003. The risk for MRSA carriage or infection in returning travellers ranged from 0.1 per million travellers returning from Nordic countries to 59.4 per million travellers returning from North Africa and the Middle East.
The authors present data on 15 individuals infected by Panton-Valentine leukocidin (PVL) -producing strains of Staphylococcus aureus. Intra-familial spread was documented in one case, and occupational transmission was most likely in another case. spa typing of the strains revealed a broad range of variants, though some strains were clonally related. Methicillin-resistant Staphylococcus aureus (MRSA) was found in three cases.
In recent years there have been a series of arguments and findings suggesting that Statins (HMG-CoA reductase inhibitors) which used widely to lower cholesterol levels may also be important in reducing the risk associated with severe infective conditions.
On the occasion of World Hand Hygiene Day, 5th May, ECDC is releasing new web pages dedicated to the Healthcare-associated Infections Surveillance Network (HAI-Net) – a European network for HAI surveillance, coordinated by ECDC.
The heptavalent pneumococcal conjugate vaccine (PCV7) targets seven of the more than 92 pneumococcal serotypes. Concerns have been raised that non-vaccine serotypes (NVTs) could increase in prevalence and reduce the benefits of vaccination. Indeed, among asymptomatic carriers, the prevalence of NVTs has increased substantially, and consequently, there has been little or no net change in the bacterial carriage prevalence.
The first annual meeting of the European hepatitis B and C surveillance network takes place on 23-24 March 2011. Since 2009, ECDC has worked on preparing the enhanced surveillance of hepatitis B and C at EU/EEA level by establishing a network for hepatitis B and C surveillance and by carrying out a survey on prevention and surveillance activities in the Member States.
ECDC and EFSA have just launched the annual report on zoonoses and food-borne outbreaks in the European Union for 2009. The report shows that Salmonella cases in humans fell by 17% in 2009, marking a decrease for the fifth consecutive year
First annual meeting of the network since it was transferred to ECDC in March 2010. Among the objectives of the meeting is to to present the epidemiological situation of diphtheria in Europe for 2009.